09 May 2023 | Tuesday | News
Image Source : Public Domain
BSI-038 is an anti-CD40 agonistic monoclonal antibody, discovered through Biosion's H³ antibody discovery platform. BSI-038 exhibits enhanced binding affinity and bioactivity when compared to Selicrelumab analog. It exhibited potent and dose-dependent anti-tumor activity in animal models. It was well tolerated in pre-clinical studies with the highest non-severely toxic dose (HNSTD) established at 150 mg/kg in non-human primates.
Biosion has a licensing agreement with Chia Tai Tianqing Pharmaceutical Group (CTTQ) in which CTTQ has an exclusive license to develop and commercialize BSI-038 (also referred to as TQB2916 by CTTQ) in Greater China. CTTQ is currently conducting a Phase 1 clinical study of BSI-038 in advanced tumors in China.